At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 target
Drug / intervention
IMMU-107 (hPAM4)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
In Brief
A Phase 2 clinical trial evaluating IMMU-107 (hPAM4) for Pancreatic Cancer. Completed, enrolled 80 participants across 11 sites.
Detailed Summary
This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionJul 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJan 29, 2008
Enrollment StartJan 1, 2008
Primary CompletionJul 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18.4 years ago
Interventions
IMMU-107 (hPAM4)biological
90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks